Company profile
Radiopharm Theranostics Ltd
NASDAQ:RADXBiotechnology: Pharmaceutical Preparations
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07189871 | phase1_2 | recruiting | 2026-02-23 | 2027-12-01 | Radiopharm Theranostics, Ltd | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors |
| NCT06305962 | — | recruiting | 2024-06-03 | 2027-12-01 | Radiopharm Theranostics, Ltd | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors |
| NCT07272642 | phase1 | not_yet_recruiting | 2026-10-30 | 2027-08-30 | Radiopharm Theranostics, Ltd | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. |
| NCT07259213 | phase1_2 | recruiting | 2026-03-05 | 2028-11-30 | Radiopharm Theranostics, Ltd | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC |
| NCT06824155 | — | recruiting | 2025-02-12 | 2027-12-01 | Radiopharm Theranostics, Ltd | HEAT Trial (HER2 Antibody Therapy With Lutetium-177) |
FDA applications (0)
No records yet.